AIM
HBIO icon

Acrospire Investment Management’s Harvard Bioscience HBIO Stock Holding History

Acrospire Investment Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-351
Closed -$9K – 621
2017
Q2 		$9K Sell
351
-3,032
-90% -$75K 0.01% 1823
2017
Q1 		$88K Sell
3,383
-3,219
-49% -$92.7K 0.07% 409
2016
Q4 		$201K Buy
6,602
+5,332
+420% +$136K 0.08% 358
2016
Q3 		$35K Buy
1,270
+662
+109% +$18.4K 0.02% 1262
2016
Q2 		$17K Buy
608
+270
+80% +$8.59K 0.01% 1582
2016
Q1 		$10K Buy
+338
New +$9.58K 0.01% 1743

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPC
Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
FP
Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

Acrospire Investment Management's HBIO Position: Q3 2017 in Review

Acrospire Investment Management sold out of Harvard Bioscience (HBIO) in Q3 2017, closing a stake of 351 shares — an estimated $9K sold.

Acrospire Investment Management first reported a position in HBIO in Q1 2016 and held it in 6 quarters. The position peaked at $201K in Q4 2016. 53 funds tracked by Wall St. Rank hold HBIO as of Q3 2017.

  • Acrospire Investment Management reported no remaining Harvard Bioscience position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 351 Harvard Bioscience shares in Q3 2017, an estimated $9K.
  • Acrospire Investment Management first reported a position in Harvard Bioscience in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Harvard Bioscience position peaked at $201K in Q4 2016.
  • 53 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.